Although information about TIGIT expression by NK cells from NB patients are still missing, published studies in different type of cancers demonstrate that TIGIT expression is high in lymphocytes of tumor patients, thus representing a targetable inhibitory immune checkpoint receptor limiting both NK- [97,98] and T-cell mediated anti-tumor activity [18,99,100,101,102,103,104]. Here, TIGIT is linked to cancer.